Arbutus Biopharma Operating Income

Arbutus Biopharma (ABUS) currently reports a operating income of $150M as of March 2026. That compares with $-91M in the prior-year period — up 269.3% year over year. Use the charts on this page to explore Arbutus Biopharma's operating income history and peer comparisons.

Arbutus Biopharma's operating income increased from $-91M to $150M — a 269.3% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arbutus Biopharma reported $150M in operating income as of March 2026. That compares with $-91M in the prior-year period — up 269.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $150M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arbutus Biopharma, and consider following ABUS for alerts when major investors trade the stock.

Arbutus Biopharma is classified in the Healthcare sector. On operating income, it currently shows $150M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ABUS with unrelated industries.